
According to data from Benzinga Pro, during Q1, Cara Therapeutics's (NASDAQ:CARA) reported sales totaled $4.79 million. Despite a 16.87% increase in earnings, the company posted a loss of $27.75 million. In Q4, Cara Therapeutics brought in $821.00 thousand in sales but lost $33.38 million in earnings.